Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Bachy, Emmanuel; F. Seymour, John; Feugier, Pierre; Offner, Fritz; López‐Guillermo, Armando; Belada, David; Xerri, Luc; Catalano, John; Brice, Pauline; Lemonnier, François; Martı́n, Alejandro; Casasnovas, Olivier; Møller Pedersen, Lars; Dorvaux, Véronique; Simpson, David; Leppä, Sirpa; Gabarre, Jean; Gomes da Silva, María; Glaisner, Sylvie; Ysebaert, Loïc; Vekhoff, Anne; Intragumtornchai, Tanin; Le Gouill, Steven; Lister, Andrew; Estell, Jane; Milone, Giuseppe; Sonet, Anne; Farhi, Jonathan; Zeuner, Harald; Tilly, Hervé; Salles, Gilles

doi:10.1200/jco.19.01073

Public

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Published in Journal of Clinical Oncology • Jul 24, 2019

Authors:

Emmanuel Bachy

John F. Seymour

Pierre Feugier

Abstract

PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582 ) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final...

Subject

Medicine

Rituximab

Follicular lymphoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!